Instituto Rosenbusch SA
BCBA:ROSE
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
83.9
380
|
| Price Target |
|
We'll email you a reminder when the closing price reaches ARS.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AR |
I
|
Instituto Rosenbusch SA
BCBA:ROSE
|
9.9B ARS |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
533.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
276.8B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
210.9B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
221.5B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
269B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
146B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
96.9B EUR |
Loading...
|
Market Distribution
| Min | -11 625% |
| 30th Percentile | -2.9% |
| Median | 7.9% |
| 70th Percentile | 12% |
| Max | 19 017.3% |
Other Profitability Ratios
Instituto Rosenbusch SA
Glance View
Instituto Rosenbusch SA engages in the manufacture and marketing of veterinary products. The company is headquartered in Buenos Aires, Buenos Aires. The company went IPO on 2008-02-21. The firm's products are structured in two lines: Pharmaceutical, including antibiotics, antimastitics products, antimycotics, antiparasites, vitamins, minerals and other chemotherapies, and Biological, comprising vaccines for cattle, equines, porks and sheeps and dogs. The company is also involved in the slaughtering and provision of meat products. As of December 31, 2011, the Company owned such subsidiaries as Laboratorios Rosenbusch SA, Laboratorios Bolivar SA and Rosenbusch Paraguay SA.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Instituto Rosenbusch SA is 14.8%, which is above its 3-year median of 4.4%.
Over the last 3 years, Instituto Rosenbusch SA’s Net Margin has increased from -3.7% to 14.8%. During this period, it reached a low of -5.3% on Sep 30, 2021 and a high of 14.8% on May 1, 2024.